Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Authors' conclusion
SGLT2 inhibitors reduce HF events and CV death in cohorts of HF, T2DM and CKD, and these effects appear consistent in patients with varying combinations of these diseases.
Study context
- Population
- Patients with heart failure (HF), T2DM or chronic kidney disease (CKD) (primary and secondary analyses of trials)
- Participants
- 90,413 patients13 trials
- Comparison
- SGLT2 inhibitors vs placebo
- Outcome
- First heart failure hospitalization (HFH)/CV death, by population
Methodological detailsrandom-effects model
- Random-effects model
Pooled result
As reported in the abstract
SGLT2 inhibitors vs PlaceboHazard ratio (95% CI)
HF; 24% risk reduction
0.76(0.72–0.81)
T2DM; 23% risk reduction
0.77(0.73–0.81)
CKD; 23% risk reduction
0.77(0.72–0.82)
Further pooled results
Cardiovascular (CV) death, by population
- Significant CV death reduction in HF
- 16%
- Significant CV death reduction in T2DM
- 15%
- Significant CV death reduction in CKD
- 12%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. J Am Coll Cardiol. Published 27 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →